

Randomized, double-blind, active-controlled trial. Moderate-to-severe UC patients were randomised to:  
 Vedolizumab induction+ 300mg e8w vs Adalimumab induction+ 40mg eow.  
 25% of the patients had previous exposure to antiTNF. Dose escalation was not permitted.

Primary outcome remission w52.

Secondary outcomes: endoscopic improvement; steroid-free remission w52.

#### Results:

- Remission w52: 31.3% VDZ vs 22.5% ADA; p=0.006
- Endoscopic improvement w52: 39.7% VDZ vs 27.7% ADA; p<0.001
- Steroid free clinical remission: 12.6% VDZ vs 21.8% ADA; p=ns

#### Conclusions:

Vedolizumab was superior to Adalimumab in moderate-severe UC with respect to clinical remission and endoscopic improvement but not steroid-free clinical remission.

## Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis

